bioMerieux (OTCMKTS:BMXMF – Get Free Report) saw unusually-high trading volume on Friday . Approximately 137 shares were traded during mid-day trading, an increase of 37% from the previous session’s volume of 100 shares.The stock last traded at $110.00 and had previously closed at $112.57.
Analyst Upgrades and Downgrades
Separately, BNP Paribas Exane cut shares of bioMerieux to a “neutral” rating in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat, bioMerieux currently has a consensus rating of “Hold”.
Get Our Latest Stock Analysis on BMXMF
bioMerieux Price Performance
bioMerieux Company Profile
bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.
Recommended Stories
- Five stocks we like better than bioMerieux
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Gold $5,000: The 2026 Gold & Silver Summit is LIVE March 4
- How a Family Trust May Be Able To Help Preserve Your Wealth
- This makes me furious
- Elon Musk: This Could Turn $100 into $100,000
Receive News & Ratings for bioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.
